|
|||
![]() |
|||
2010-06-10 12:40:00 CEST 2010-06-10 12:40:14 CEST REGULATED INFORMATION Biohit Oyj - Changes board/management/auditorsNEW PRESIDENT AND CEO FOR BIOHIT OYJBIOHIT OYJ STOCK EXCHANGE RELEASE ON 10 JUNE 2010 AT 1:40 PM NEW PRESIDENT AND CEO FOR BIOHIT OYJ Professor Osmo Suovaniemi, 66, founder of Biohit, today announced his resignation from his position as President and CEO of the company. As of 10 June 2010, his duties will be taken over by Jussi Heiniö, 48, LLM. Mr Heiniö has been with Biohit since 1997 and for the last six years he has served as the company's VP of Administration and Legal Affairs, and as Executive Vice President. Additionally, he has acted as Chairman of the Board of all subsidiaries and has been actively involved in the development of their local business activities, particularly in emerging markets. "Jussi Heiniö is the natural choice as Osmo Suovaniemi's successor. He knows the company, its markets and challenges, so we are confident that, together with our expert staff, he will be able to steer the company towards success", affirms Reijo Luostarinen, Chairman of the Board of Biohit Oyj. "Biohit has grown into a global player with employees in 11 countries on three continents", Heiniö comments. "It is my goal to develop the company's business in a truly international direction, by utilising the Group's own resources and large network of subsidiaries. We offer unique innovations, first-rate products and highly skilled personnel. Osmo Suovaniemi has made Biohit a success with his inventions and fearless approach, and I am very excited about having the opportunity to continue this story." Osmo Suovaniemi is not leaving the company. He continues to take active part in the development of innovations in his future roles as Chairman of the Board of Scientific Advisors. In addition, he will continue as a member of Biohit Oyj's Board of Directors. JUKKA ANT-WUORINEN NAMED NEW DEPUTY CHAIRMAN OF THE BOARD In its meeting of today, the Board of Directors of Biohit Oyj named Jukka Ant-Wuorinen, B.Sc. (Econ.) deputy chairman of the Board. Professor Reijo Luostarinen continues as chairman. Board of Directors of Biohit Oyj Further information: Osmo Suovaniemi, M.D., Ph.D., Professor Tel: +358-9-773 861 GSM: +358-40-745 5605 Email: osmo.suovaniemi@biohit.com Pictures: Josefin Hoviniemi Tel: +358-09-7738 6363 Email: josefin.hoviniemi@biohit.com Distribution: NASDAQ OMX Helsinki Oy Central storage facility (www.oam.fi) Press www.biohit.com About Biohit Oyj Established in 1988, Biohit Oyj is a Finnish biotechnology company, acting on the global market. Biohit's operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective liquid handling solutions for laboratory work as well as diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. Biohit has two business segments: liquid handling and diagnostics. Liquid handling products include electronic and mechanical pipettes, disposable tips as well as pipette maintenance and calibration services for research institutions, healthcare and industrial laboratories. The diagnostics business comprises products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and H. pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of intestinal bleeding that indicates a risk of colorectal cancer. The Acetium innovation reduces carcinogenic acetaldehyde in anacidic stomachs. The Biohit Group employs around 390 people. The company is headquartered in Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA, as well as a representative office in Singapore. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare since 1999. Read more at www.biohit.com |
|||
|